

David de la Rosa Carrillo

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7541355/publications.pdf>

Version: 2024-02-01

47
papers

2,058
citations

304743

22
h-index

243625

44
g-index

50
all docs

50
docs citations

50
times ranked

1476
citing authors

#	ARTICLE	IF	CITATIONS
1	Effectiveness and Safety of Inhaled Antibiotics in Patients With Chronic Obstructive Pulmonary Disease. A Multicentre Observational Study. <i>Archivos De Bronconeumologia</i> , 2022, 58, 11-21.	0.8	25
2	Systemic Inflammatory Biomarkers Define Specific Clusters in Patients with Bronchiectasis: A Large-Cohort Study. <i>Biomedicines</i> , 2022, 10, 225.	3.2	4
3	Short and Long-Term Impact of COVID-19 Infection on Previous Respiratory Diseases. <i>Archivos De Bronconeumologia</i> , 2022, 58, 39-50.	0.8	26
4	Blood Neutrophil Counts Define Specific Clusters of Bronchiectasis Patients: A Hint to Differential Clinical Phenotypes. <i>Biomedicines</i> , 2022, 10, 1044.	3.2	7
5	Chronic Bronchial Infection Is Associated with More Rapid Lung Function Decline in Chronic Obstructive Pulmonary Disease. <i>Annals of the American Thoracic Society</i> , 2022, 19, 1842-1847.	3.2	17
6	Impact of Chronic Bronchial Infection by <i>Staphylococcus aureus</i> on Bronchiectasis. <i>Journal of Clinical Medicine</i> , 2022, 11, 3960.	2.4	4
7	Bronchial Infection and Temporal Evolution of Bronchiectasis in Patients With Chronic Obstructive Pulmonary Disease. <i>Clinical Infectious Diseases</i> , 2021, 72, 403-410.	5.8	33
8	RIBRON: el registro espa�ol informatizado de bronquiectasias. Caracterizaci3n de los primeros 1.912 pacientes. <i>Archivos De Bronconeumologia</i> , 2021, 57, 28-35.	0.8	44
9	Coagulation disorders and thromboembolic disease in COVID-19: review of current evidence in search of a better approach. <i>Journal of Thoracic Disease</i> , 2021, 13, 1239-1255.	1.4	15
10	Evolution and Comparative Analysis of Hospitalizations in Spain Due to COPD and Bronchiectasis between 2004 and 2015. <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , 2021, 18, 210-218.	1.6	2
11	Risk Factors and Relation with Mortality of a New Acquisition and Persistence of <i>Pseudomonas aeruginosa</i> in COPD Patients. <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , 2021, 18, 333-340.	1.6	14
12	Differences in Nutritional Status and Inflammatory Biomarkers between Female and Male Patients with Bronchiectasis: A Large-Cohort Study. <i>Biomedicines</i> , 2021, 9, 905.	3.2	5
13	One year on: Are we ready for COVID?. <i>Archivos De Bronconeumologia</i> , 2021, 57, 517-518.	0.8	0
14	Y un a�o despu�s, �estamos preparados para la COVID?. <i>Archivos De Bronconeumologia</i> , 2021, 57, 517-518.	0.8	0
15	Phenotypic Clustering in Non-Cystic Fibrosis Bronchiectasis Patients: The Role of Eosinophils in Disease Severity. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 8431.	2.6	21
16	C-Reactive Protein Concentration in Steady-State Bronchiectasis: Prognostic Value of Future Severe Exacerbations. Data From the Spanish Registry of Bronchiectasis (RIBRON). <i>Archivos De Bronconeumologia</i> , 2021, 57, 21-27.	0.8	35
17	COPD Assessment Test in Bronchiectasis: Minimum Clinically Important Difference and Psychometric Validation. <i>Chest</i> , 2020, 157, 824-833.	0.8	16
18	The Roles of Bacteria and Viruses in Bronchiectasis Exacerbation: A Prospective Study. <i>Archivos De Bronconeumologia</i> , 2020, 56, 621-629.	0.8	9

#	ARTICLE	IF	CITATIONS
19	Consensus document on the diagnosis and treatment of chronic bronchial infection in chronic obstructive pulmonary disease. <i>Archivos De Bronconeumologia</i> , 2020, 56, 651-664.	0.8	20
20	Impact of <i>Pseudomonas aeruginosa</i> Infection on Patients with Chronic Inflammatory Airway Diseases. <i>Journal of Clinical Medicine</i> , 2020, 9, 3800.	2.4	63
21	Inhaled Dry Powder Antibiotics in Patients with Non-Cystic Fibrosis Bronchiectasis: Efficacy and Safety in a Real-Life Study. <i>Journal of Clinical Medicine</i> , 2020, 9, 2317.	2.4	6
22	The Role of Epstein-Barr Virus in Adults With Bronchiectasis: A Prospective Cohort Study. <i>Open Forum Infectious Diseases</i> , 2020, 7, ofaa235.	0.9	11
23	Current Challenges in Chronic Bronchial Infection in Patients with Chronic Obstructive Pulmonary Disease. <i>Journal of Clinical Medicine</i> , 2020, 9, 1639.	2.4	23
24	Inhaled Steroids, Circulating Eosinophils, Chronic Airway Infection, and Pneumonia Risk in Chronic Obstructive Pulmonary Disease. A Network Analysis. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2020, 201, 1078-1085.	5.6	78
25	The Roles of Bacteria and Viruses in Bronchiectasis Exacerbation: A Prospective Study. <i>Archivos De Bronconeumologia</i> , 2020, 56, 621-629.	0.8	32
26	Desabastecimiento de fármacos antituberculosos en combinación en España. <i>Archivos De Bronconeumologia</i> , 2020, 56, 118-119.	0.8	0
27	Las bronquiectasias: una enfermedad compleja y heterogénea. <i>Archivos De Bronconeumologia</i> , 2019, 55, 427-433.	0.8	16
28	The significant global economic burden of bronchiectasis: a pending matter. <i>European Respiratory Journal</i> , 2019, 53, 1802392.	6.7	19
29	Prognostic Value of Frequent Exacerbations in Bronchiectasis: The Relationship With Disease Severity. <i>Archivos De Bronconeumologia</i> , 2019, 55, 81-87.	0.8	37
30	Bronquiectasias: cuando la evidencia científica publicada no resulta suficiente. <i>Archivos De Bronconeumologia</i> , 2019, 55, 283-285.	0.8	10
31	The annual prognostic ability of FACED and E-FACED scores to predict mortality in patients with bronchiectasis. <i>ERJ Open Research</i> , 2018, 4, 00139-2017.	2.6	13
32	Spanish Guidelines on the Evaluation and Diagnosis of Bronchiectasis in Adults. <i>Archivos De Bronconeumologia</i> , 2018, 54, 79-87.	0.8	57
33	Spanish Guidelines on Treatment of Bronchiectasis in Adults. <i>Archivos De Bronconeumologia</i> , 2018, 54, 88-98.	0.8	107
34	Normativa sobre la valoración y el diagnóstico de las bronquiectasias en el adulto. <i>Archivos De Bronconeumologia</i> , 2018, 54, 79-87.	0.8	71
35	Normativa sobre el tratamiento de las bronquiectasias en el adulto. <i>Archivos De Bronconeumologia</i> , 2018, 54, 88-98.	0.8	98
36	Bronquiectasias: resurgiendo de sus propias cenizas. <i>Archivos De Bronconeumologia</i> , 2018, 54, 59-60.	0.8	2

#	ARTICLE	IF	CITATIONS
37	Current and future pharmacotherapy options for non-cystic fibrosis bronchiectasis. Expert Review of Respiratory Medicine, 2018, 12, 569-584.	2.5	8
38	Cost of Hospitalizations due to Exacerbation in Patients with Non-Cystic Fibrosis Bronchiectasis. Respiration, 2018, 96, 406-416.	2.6	22
39	Etiología de las bronquiectasias en una cohorte de 2.047 pacientes. Análisis del registro histórico español. Archivos De Bronconeumología, 2017, 53, 366-374.	0.8	67
40	Latin America validation of FACED score in patients with bronchiectasis: an analysis of six cohorts. BMC Pulmonary Medicine, 2017, 17, 73.	2.0	26
41	Predicting high risk of exacerbations in bronchiectasis: the E-FACED score. International Journal of COPD, 2017, Volume 12, 275-284.	2.3	138
42	Clinical impact of chronic obstructive pulmonary disease on non-cystic fibrosis bronchiectasis. A study on 1,790 patients from the Spanish Bronchiectasis Historical Registry. PLoS ONE, 2017, 12, e0177931.	2.5	22
43	Treatment of patients with COPD and recurrent exacerbations: the role of infection and inflammation. International Journal of COPD, 2016, 11, 515.	2.3	37
44	Annual direct medical costs of bronchiectasis treatment. Chronic Respiratory Disease, 2016, 13, 361-371.	2.4	61
45	The Multiple Faces of Non-Cystic Fibrosis Bronchiectasis. A Cluster Analysis Approach. Annals of the American Thoracic Society, 2016, 13, 1468-1475.	3.2	60
46	Multidimensional approach to non-cystic fibrosis bronchiectasis: the FACED score. European Respiratory Journal, 2014, 43, 1357-1367.	6.7	372
47	Prognostic Value of Bronchiectasis in Patients with Moderate-to-Severe Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2013, 187, 823-831.	5.6	263